<DOC>
	<DOC>NCT00704769</DOC>
	<brief_summary>Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.</brief_summary>
	<brief_title>Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)</brief_title>
	<detailed_description>Children, ages 2-11, with a history of perennial allergic rhinitis</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>Children patients of both sexes aged between 211 years, of either gender and any race Unequivocal history of perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation Minimum score for inclusion: 10 Capable of complying with the dosing regimen Free of any clinically significant disease (other than allergic rhinitis) Antihistamine must be justified by investigating doctor Patients with asthma who require chronic use of inhaled or systemic corticosteroids History of frequent, clinically significant sinusitis or chronic purulent postnasal drip Patients with rhinitis medicamentosa History of hypersensitivity to desloratadine or any of its excipients Doctor deems unsuitable</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>